alt
TNBC Patient
Complete the form to get the full interpretation guide 
 

The VENTANA PD-L1 (SP142) Assay is the first and only CDx that’s FDA approved to help identify triple-negative breast cancer (TNBC) patients eligible for TECENTRIQ® (atezolizumab).1,2  You can run this assay on your BenchMark ULTRA system or send it to one of our testing centers.

Success
Form submitted successfully
text

We value your privacy.

 
Find testing sites offering theVENTANA PD-L1 (SP142) Assay
Want to learn more?
alt
PD-L1 educational videos
 

Learn about the tumor microenvironment, PD-L1 expression on immune and tumor cells and the development process for companion diagnostic tests.

alt
Webcast training
 

Watch our online microscopy training, “Scoring the VENTANA PD-L1 (SP142) Assay for the TNBC indication,” hosted by Roche Medical and Scientific Affairs Pathologists.

alt
Roche Diagnostics University
 

Find online training courses for the VENTANA PD-L1 (SP142) Assay. Topics include PD-L1 expression, the tumor microenvironment and information on the other cancer indications.

In addition to TNBC, the VENTANA PD-L1 (SP142) Assay is also indicated for:
Urothelial Carcinoma
 

The VENTANA PD-L1 (SP142) Assay* is the first and only FDA-approved test predictive for TECENTRIQ® (atezolizumab) in urothelial carcinoma (UC) patients. It is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.

*In the US available only on the VENTANA BenchMark ULTRA automated slide staining instrument.

Non-Small Cell Lung Cancer
 

The VENTANA PD-L1 (SP142) Assay is the first to evaluate patient PD-L1 expression using both tumor cell (TC) and tumor-infiltrating immune cell (IC) staining. Determining a patient’s PD-L1 expression level can give insight to the overall survival that may be achieved from TECENTRIQ® (atezolizumab).*

*All randomized patients in an NSCLC phase III study observed benefit from TECENTRIQ® (atezolizumab) regardless of PD-L1 status.